Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Schrodinger
Biotech
Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax
Lilly’s run of near-weekly acquisitions shows no sign of letting up, with the pharma now buying Ajax for its clinical-stage myelofibrosis therapy.
James Waldron
Apr 27, 2026 8:25am
Schrödinger abandons CDC7 inhibitor linked to 2 patient deaths
Aug 14, 2025 8:23am
20-year Novo vet lands first CEO role—Chutes & Ladders
May 30, 2025 8:30am
Schrödinger lays off 60 workers to reduce cash burn
May 20, 2025 12:53pm
Novartis pays Schrödinger $150M to form drug discovery pact
Nov 12, 2024 8:55am
JPM23's Medtech Tidbits: Reporting from San Francisco
Jan 11, 2023 11:11am
